2003
DOI: 10.1016/s0016-5085(03)81083-1
|View full text |Cite
|
Sign up to set email alerts
|

Antineutrophil cytoplasmic antibody in patients with ulcerative colitis: Relation to clinical course

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2006
2006
2006
2006

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…Generally, perinuclear antineutrophil cytoplasmic autoantibody (pANCA) is recognized as a marker of a subgroup of patients with UC. [10][11][12] Anti-Saccharomyces cerevisiae antibody (ASCA) is directed against the oligomannosidic epitope of the yeast S. cerevisiae. 13 The ASCA positive rate is high in patients with CD, [13][14][15] but little is known about the association of serologic markers, such as ASCA and intestinal BD.…”
mentioning
confidence: 99%
“…Generally, perinuclear antineutrophil cytoplasmic autoantibody (pANCA) is recognized as a marker of a subgroup of patients with UC. [10][11][12] Anti-Saccharomyces cerevisiae antibody (ASCA) is directed against the oligomannosidic epitope of the yeast S. cerevisiae. 13 The ASCA positive rate is high in patients with CD, [13][14][15] but little is known about the association of serologic markers, such as ASCA and intestinal BD.…”
mentioning
confidence: 99%